Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Medro vs VitaFusions IV

Medro
Graded #252

Higher grade

vs+1.3000000000000043
VitaFusions IV
Graded #274

Lower grade

The verdict

Medro takes it — 63.6/100 to 62.3/100, but only just.

Medro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, via a partner medical group and… VitaFusions IV is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueVitaFusions IV +9
50
59
Dose & formulationMedro +5
77
72
Clinical oversightVitaFusions IV +3
71
74
Labs & monitoringVitaFusions IV +1
52
53
FulfillmentMedro +30
92
62
Contract termsVitaFusions IV +4
33
37
Medro · left barVitaFusions IV · right bar

The numbers

MetricMedroVitaFusions IV
WeighScore63.6/10062.3/100
GradeCC
Scorecard rank#252#274
Semaglutide$199/mo (compounded)$149/mo (all doses, plus a separate fee, compounded)
Tirzepatide$299/mo (compounded)$189/mo (all doses, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Medro

Graded #252 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
VitaFusions IV

Graded #274 · C

Strengths

  • Semaglutide confirmed from page metadata
  • Published flat package pricing: semaglutide from $149, tirzepatide $189 for a 7-week supply, no insurance/memberships/contracts

Where it loses points

  • Advertised prices are 7-week package prices, not monthly; homepage banner ('$199 for 7 weeks') conflicts with the program page ('Starting $149')

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard